Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation

A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure t...

Conference on Alzheimer’s reveals several advances in the field

In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Sci...

Astra Zeneca lägger ut miljonbelopp i Ryssland – ”Varken acceptabelt eller försvarligt”

Svensk-brittiska Astra Zeneca har spenderat mångmiljonbelopp i Ryssland efter krigsutbrottet. Det handlar bland annat om bidrag, donationer, genomföranden av st...

We desire talent to come here, but are we genuinely welcoming them?

Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...

Därför skyr Big Pharma Storbritannien – miljardinvesteringar fryses

Läkemedelsjättar har skrotat eller pausat investeringar för nära två miljarder pund i Storbritannien hittills i år. Ett ”alltmer utmanande” klimat för innovatio...

When carelessness, forgetfulness and coincidence become the researcher’s best friend

Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advanc...

Automated dispensing of a viscous hydrogel

A suitable solution developed for UPM Biomedicals In the Festo LifeTech Application Center we tested a setup for UPM Biomedicals for the automatic dispensing of...

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive ...

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...

Nu tar vi Bioscience till Göteborg

Life Science Sweden håller för första gången ett event i Göteborg.

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

The first vaccine derived from cowpox

The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the ...

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

The Swedish National Board of Health and Welfare rejects prioritising andrology as a speciality

Male infertility can be linked to a shorter lifespan and several severe diseases, but when couples who want children are examined, the focus is on the woman. Ex...

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...

The most important Swedish medical innovations: Our ranking

Life Science Sweden turns 20 years old – and celebrates by producing a top list of the 20 most important contemporary Swedish innovations in the field of medicine.

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working...

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Novo Nordisk tappar efter resultat från fetmastudie

Danska läkemedelsbolaget Novo Nordisk faller med runt 5 procent på börsen efter att ha aviserat resultat från fas III-studien Redefine 2 med Cagrisema.

Automated opening and closing of sample vials

From technical requirements to a suitable solution

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)